Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $54.4 million.

  • Harvard Bioscience's Total Current Liabilities rose 13909.28% to $54.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.4 million, marking a year-over-year increase of 13909.28%. This contributed to the annual value of $55.0 million for FY2024, which is 10706.05% up from last year.
  • Per Harvard Bioscience's latest filing, its Total Current Liabilities stood at $54.4 million for Q3 2025, which was up 13909.28% from $55.2 million recorded in Q2 2025.
  • Harvard Bioscience's 5-year Total Current Liabilities high stood at $55.6 million for Q1 2025, and its period low was $20.7 million during Q1 2021.
  • Moreover, its 5-year median value for Total Current Liabilities was $23.5 million (2021), whereas its average is $30.3 million.
  • Per our database at Business Quant, Harvard Bioscience's Total Current Liabilities plummeted by 1472.49% in 2023 and then skyrocketed by 14402.99% in 2025.
  • Quarter analysis of 5 years shows Harvard Bioscience's Total Current Liabilities stood at $25.3 million in 2021, then dropped by 8.16% to $23.2 million in 2022, then rose by 14.16% to $26.5 million in 2023, then skyrocketed by 107.06% to $55.0 million in 2024, then decreased by 1.02% to $54.4 million in 2025.
  • Its last three reported values are $54.4 million in Q3 2025, $55.2 million for Q2 2025, and $55.6 million during Q1 2025.